

Mehrad Tavallai

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11073556/mehrad-tavallai-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

294
citations

10
h-index

10
g-index

10
ext. papers

343
ext. citations

6.5
avg, IF

2.65
L-index

#	Paper	IF	Citations
10	GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. <i>Journal of Cellular Physiology</i> , 2015 , 230, 2552-78	7	41
9	The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. <i>Oncotarget</i> , 2016 , 7, 19620-30	3.3	40
8	Nexavar/Stivarga and viagra interact to kill tumor cells. <i>Journal of Cellular Physiology</i> , 2015 , 230, 2281-98		37
7	Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. <i>Oncotarget</i> , 2016 , 7, 12975-96	3.3	35
6	OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. <i>Journal of Cellular Physiology</i> , 2015 , 230, 1982-98	7	34
5	Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic. <i>Frontiers in Oncology</i> , 2016 , 6, 142	5.3	28
4	[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFB compensatory survival signaling. <i>Oncotarget</i> , 2016 , 7, 23608-32	3.3	25
3	Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. <i>Cancer Discovery</i> , 2018 , 8, 336-353	24.4	21
2	Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. <i>Oncotarget</i> , 2016 , 7, 40398-40417	3.3	17
1	Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS. <i>Oncotarget</i> , 2016 , 7, 17290-300	3.3	16